PIK3CA mutations rare in RCC; mTORi (everolimus, temsirolimus) approved 2L+ regardless of...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-PIK3CA-HOTSPOT-RCC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-RCC |
| Sources | SRC-CIVIC SRC-NCCN-KIDNEY-2025 |
Actionability Facts
| Biomarker | BIO-PIK3CA-MUTATION |
|---|---|
| Variant | hotspot (E545K / E542K / H1047R) |
| Disease | DIS-RCC |
| ESCAT tier | IIIB |
| Evidence summary | PIK3CA mutations rare in RCC; mTORi (everolimus, temsirolimus) approved 2L+ regardless of PIK3CA status. |
Notes
ESCAT IIIB. Tissue-agnostic capivasertib limited to HR+/HER2- breast.
Used By
No reverse references found in the YAML corpus.